Global X Genomics & Biotechnology ETF company info

What does Global X Genomics & Biotechnology ETF do?
Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) focuses on investment opportunities within the genomics and biotechnology sector, aiming to provide investors with exposure to companies involved in gene editing, genomic sequencing, and biotechnological innovation. This ETF selects companies at the forefront of genetic engineering, diagnostic solutions, and personalized medicine, aiming to capitalize on the rapid advancements in these areas. Its objective is to offer long-term capital growth by tracking the performance of the Solactive Genomics Index, which encompasses firms globally that stand to potentially benefit from further advances and applications in the field of genomics. By investing in Global X Genomics & Biotechnology ETF, investors get exposure to a cutting-edge sector that is poised to revolutionize healthcare, agriculture, and pharmaceuticals among other industries.
Global X Genomics & Biotechnology ETF company media
Company Snapshot

Is Global X Genomics & Biotechnology ETF a public or private company?

key
Ownership
Public

How many people does Global X Genomics & Biotechnology ETF employ?

people
Employees
206

What sector is Global X Genomics & Biotechnology ETF in?

pie chart
Sector
ETF

Where is the head office for Global X Genomics & Biotechnology ETF?

location pin
Head Office
New York, United States

What year was Global X Genomics & Biotechnology ETF founded?

founded flag
Year Founded
2019
What does Global X Genomics & Biotechnology ETF specialise in?
/Genomics Investments /Biotechnology Stocks /Index Tracking /Diversified Portfolio /ETF Management /Investment Services

What are the products and/or services of Global X Genomics & Biotechnology ETF?

Overview of Global X Genomics & Biotechnology ETF offerings
Invests in companies involved in genomics and biotechnology, aiming to benefit from advances in genetic engineering and diagnostics.
Focuses on firms developing treatments for rare genetic diseases, aiming to improve patient outcomes and quality of life.
Supports companies engaging in CRISPR technology for precise DNA editing, fostering innovations in disease treatment.
Backs businesses in personalized medicine, utilizing genetic information to tailor treatments to individual genetic profiles.
Invests in agricultural biotechnology companies improving crop yield and resistance, contributing to food security.
Promotes investments in companies advancing reproductive genetics, enhancing fertility treatments and genetic screening.